Report cover image

Global Pharmaceutical Intermediate CDMO Market Growth (Status and Outlook) 2023-2029

Publisher LP Information, Inc.
Published Aug 04, 2023
Length 110 Pages
SKU # LPI18097359

Description

Global Pharmaceutical Intermediate CDMO Market Growth (Status and Outlook) 2023-2029


According to our (LP Info Research) latest study, the global Pharmaceutical Intermediate CDMO market size was valued at US$ million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Pharmaceutical Intermediate CDMO is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.

The research report highlights the growth potential of the global Pharmaceutical Intermediate CDMO market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Pharmaceutical Intermediate CDMO are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Pharmaceutical Intermediate CDMO. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Pharmaceutical Intermediate CDMO market.

Key Features:

The report on Pharmaceutical Intermediate CDMO market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Pharmaceutical Intermediate CDMO market. It may include historical data, market segmentation by Type (e.g., Small Molecule Cdmo, Macromolecular Cdmo), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Pharmaceutical Intermediate CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Pharmaceutical Intermediate CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Pharmaceutical Intermediate CDMO industry. This include advancements in Pharmaceutical Intermediate CDMO technology, Pharmaceutical Intermediate CDMO new entrants, Pharmaceutical Intermediate CDMO new investment, and other innovations that are shaping the future of Pharmaceutical Intermediate CDMO.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Pharmaceutical Intermediate CDMO market. It includes factors influencing customer ' purchasing decisions, preferences for Pharmaceutical Intermediate CDMO product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Pharmaceutical Intermediate CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Pharmaceutical Intermediate CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Pharmaceutical Intermediate CDMO market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Pharmaceutical Intermediate CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Pharmaceutical Intermediate CDMO market.

Market Segmentation:

Pharmaceutical Intermediate CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Segmentation by type

Small Molecule Cdmo

Macromolecular Cdmo

Segmentation by application

Pharmaceutical Company

Biotechnology Company

Others

This report also splits the market by region:

Americas
United States
Canada
Mexico
Brazil

APAC
China
Japan
Korea
Southeast Asia
India
Australia

Europe
Germany
France
UK
Italy
Russia

Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Cambrex

WR Grace

Esteve Química

AGC Pharma Chemicals

Evonik

CordenPharma

Otsuka Chemical

Wavelength

KBI Biopharma

Chengda Pharmaceuticals

Apeloa Pharmaceutical

Xi'an Manareco New Materials

Shenzhen Sungening Bio-technology

Chengdu D-innovation Pharmaceutical

Huateng Pharma

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

110 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pharmaceutical Intermediate CDMO Market Size 2018-2029
2.1.2 Pharmaceutical Intermediate CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Pharmaceutical Intermediate CDMO Segment by Type
2.2.1 Small Molecule Cdmo
2.2.2 Macromolecular Cdmo
2.3 Pharmaceutical Intermediate CDMO Market Size by Type
2.3.1 Pharmaceutical Intermediate CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Pharmaceutical Intermediate CDMO Market Size Market Share by Type (2018-2023)
2.4 Pharmaceutical Intermediate CDMO Segment by Application
2.4.1 Pharmaceutical Company
2.4.2 Biotechnology Company
2.4.3 Others
2.5 Pharmaceutical Intermediate CDMO Market Size by Application
2.5.1 Pharmaceutical Intermediate CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Pharmaceutical Intermediate CDMO Market Size Market Share by Application (2018-2023)
3 Pharmaceutical Intermediate CDMO Market Size by Player
3.1 Pharmaceutical Intermediate CDMO Market Size Market Share by Players
3.1.1 Global Pharmaceutical Intermediate CDMO Revenue by Players (2018-2023)
3.1.2 Global Pharmaceutical Intermediate CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Pharmaceutical Intermediate CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Pharmaceutical Intermediate CDMO by Regions
4.1 Pharmaceutical Intermediate CDMO Market Size by Regions (2018-2023)
4.2 Americas Pharmaceutical Intermediate CDMO Market Size Growth (2018-2023)
4.3 APAC Pharmaceutical Intermediate CDMO Market Size Growth (2018-2023)
4.4 Europe Pharmaceutical Intermediate CDMO Market Size Growth (2018-2023)
4.5 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size Growth (2018-2023)
5 Americas
5.1 Americas Pharmaceutical Intermediate CDMO Market Size by Country (2018-2023)
5.2 Americas Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
5.3 Americas Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pharmaceutical Intermediate CDMO Market Size by Region (2018-2023)
6.2 APAC Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
6.3 APAC Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Pharmaceutical Intermediate CDMO by Country (2018-2023)
7.2 Europe Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
7.3 Europe Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Pharmaceutical Intermediate CDMO by Region (2018-2023)
8.2 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size by Type (2018-2023)
8.3 Middle East & Africa Pharmaceutical Intermediate CDMO Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Pharmaceutical Intermediate CDMO Market Forecast
10.1 Global Pharmaceutical Intermediate CDMO Forecast by Regions (2024-2029)
10.1.1 Global Pharmaceutical Intermediate CDMO Forecast by Regions (2024-2029)
10.1.2 Americas Pharmaceutical Intermediate CDMO Forecast
10.1.3 APAC Pharmaceutical Intermediate CDMO Forecast
10.1.4 Europe Pharmaceutical Intermediate CDMO Forecast
10.1.5 Middle East & Africa Pharmaceutical Intermediate CDMO Forecast
10.2 Americas Pharmaceutical Intermediate CDMO Forecast by Country (2024-2029)
10.2.1 United States Pharmaceutical Intermediate CDMO Market Forecast
10.2.2 Canada Pharmaceutical Intermediate CDMO Market Forecast
10.2.3 Mexico Pharmaceutical Intermediate CDMO Market Forecast
10.2.4 Brazil Pharmaceutical Intermediate CDMO Market Forecast
10.3 APAC Pharmaceutical Intermediate CDMO Forecast by Region (2024-2029)
10.3.1 China Pharmaceutical Intermediate CDMO Market Forecast
10.3.2 Japan Pharmaceutical Intermediate CDMO Market Forecast
10.3.3 Korea Pharmaceutical Intermediate CDMO Market Forecast
10.3.4 Southeast Asia Pharmaceutical Intermediate CDMO Market Forecast
10.3.5 India Pharmaceutical Intermediate CDMO Market Forecast
10.3.6 Australia Pharmaceutical Intermediate CDMO Market Forecast
10.4 Europe Pharmaceutical Intermediate CDMO Forecast by Country (2024-2029)
10.4.1 Germany Pharmaceutical Intermediate CDMO Market Forecast
10.4.2 France Pharmaceutical Intermediate CDMO Market Forecast
10.4.3 UK Pharmaceutical Intermediate CDMO Market Forecast
10.4.4 Italy Pharmaceutical Intermediate CDMO Market Forecast
10.4.5 Russia Pharmaceutical Intermediate CDMO Market Forecast
10.5 Middle East & Africa Pharmaceutical Intermediate CDMO Forecast by Region (2024-2029)
10.5.1 Egypt Pharmaceutical Intermediate CDMO Market Forecast
10.5.2 South Africa Pharmaceutical Intermediate CDMO Market Forecast
10.5.3 Israel Pharmaceutical Intermediate CDMO Market Forecast
10.5.4 Turkey Pharmaceutical Intermediate CDMO Market Forecast
10.5.5 GCC Countries Pharmaceutical Intermediate CDMO Market Forecast
10.6 Global Pharmaceutical Intermediate CDMO Forecast by Type (2024-2029)
10.7 Global Pharmaceutical Intermediate CDMO Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Cambrex
11.1.1 Cambrex Company Information
11.1.2 Cambrex Pharmaceutical Intermediate CDMO Product Offered
11.1.3 Cambrex Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Cambrex Main Business Overview
11.1.5 Cambrex Latest Developments
11.2 WR Grace
11.2.1 WR Grace Company Information
11.2.2 WR Grace Pharmaceutical Intermediate CDMO Product Offered
11.2.3 WR Grace Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 WR Grace Main Business Overview
11.2.5 WR Grace Latest Developments
11.3 Esteve Química
11.3.1 Esteve Química Company Information
11.3.2 Esteve Química Pharmaceutical Intermediate CDMO Product Offered
11.3.3 Esteve Química Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Esteve Química Main Business Overview
11.3.5 Esteve Química Latest Developments
11.4 AGC Pharma Chemicals
11.4.1 AGC Pharma Chemicals Company Information
11.4.2 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Product Offered
11.4.3 AGC Pharma Chemicals Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 AGC Pharma Chemicals Main Business Overview
11.4.5 AGC Pharma Chemicals Latest Developments
11.5 Evonik
11.5.1 Evonik Company Information
11.5.2 Evonik Pharmaceutical Intermediate CDMO Product Offered
11.5.3 Evonik Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Evonik Main Business Overview
11.5.5 Evonik Latest Developments
11.6 CordenPharma
11.6.1 CordenPharma Company Information
11.6.2 CordenPharma Pharmaceutical Intermediate CDMO Product Offered
11.6.3 CordenPharma Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 CordenPharma Main Business Overview
11.6.5 CordenPharma Latest Developments
11.7 Otsuka Chemical
11.7.1 Otsuka Chemical Company Information
11.7.2 Otsuka Chemical Pharmaceutical Intermediate CDMO Product Offered
11.7.3 Otsuka Chemical Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Otsuka Chemical Main Business Overview
11.7.5 Otsuka Chemical Latest Developments
11.8 Wavelength
11.8.1 Wavelength Company Information
11.8.2 Wavelength Pharmaceutical Intermediate CDMO Product Offered
11.8.3 Wavelength Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Wavelength Main Business Overview
11.8.5 Wavelength Latest Developments
11.9 KBI Biopharma
11.9.1 KBI Biopharma Company Information
11.9.2 KBI Biopharma Pharmaceutical Intermediate CDMO Product Offered
11.9.3 KBI Biopharma Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 KBI Biopharma Main Business Overview
11.9.5 KBI Biopharma Latest Developments
11.10 Chengda Pharmaceuticals
11.10.1 Chengda Pharmaceuticals Company Information
11.10.2 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Product Offered
11.10.3 Chengda Pharmaceuticals Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Chengda Pharmaceuticals Main Business Overview
11.10.5 Chengda Pharmaceuticals Latest Developments
11.11 Apeloa Pharmaceutical
11.11.1 Apeloa Pharmaceutical Company Information
11.11.2 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Product Offered
11.11.3 Apeloa Pharmaceutical Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Apeloa Pharmaceutical Main Business Overview
11.11.5 Apeloa Pharmaceutical Latest Developments
11.12 Xi'an Manareco New Materials
11.12.1 Xi'an Manareco New Materials Company Information
11.12.2 Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Product Offered
11.12.3 Xi'an Manareco New Materials Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Xi'an Manareco New Materials Main Business Overview
11.12.5 Xi'an Manareco New Materials Latest Developments
11.13 Shenzhen Sungening Bio-technology
11.13.1 Shenzhen Sungening Bio-technology Company Information
11.13.2 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Product Offered
11.13.3 Shenzhen Sungening Bio-technology Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Shenzhen Sungening Bio-technology Main Business Overview
11.13.5 Shenzhen Sungening Bio-technology Latest Developments
11.14 Chengdu D-innovation Pharmaceutical
11.14.1 Chengdu D-innovation Pharmaceutical Company Information
11.14.2 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Product Offered
11.14.3 Chengdu D-innovation Pharmaceutical Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Chengdu D-innovation Pharmaceutical Main Business Overview
11.14.5 Chengdu D-innovation Pharmaceutical Latest Developments
11.15 Huateng Pharma
11.15.1 Huateng Pharma Company Information
11.15.2 Huateng Pharma Pharmaceutical Intermediate CDMO Product Offered
11.15.3 Huateng Pharma Pharmaceutical Intermediate CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Huateng Pharma Main Business Overview
11.15.5 Huateng Pharma Latest Developments
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us